What question did this study set out to answer?

This study aims to evaluate the factors associated with the omission of axillary lymph node dissection in patients with clinical node-positive breast cancer who have residual disease after neoadjuvant chemotherapy.

June 28, 2026Annals of Surgical OncologyOpen Access

Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy

View Full Paper

Ask AI

Bookmark

Authors

NRNicole RademacherUniversity of Alabama at Birmingham LGLily A. GutnikUniversity of Alabama at Birmingham KBK. BromanThe University of Texas MD Anderson Cancer Center

Discussion

Member takes

Implication

Retrospective observational study evaluates factors leading to omission of axillary dissection in patients with residual nodal disease after neoadjuvant chemotherapy, indicating evolving treatment...

Key Points

This study aims to evaluate the factors associated with the omission of axillary lymph node dissection in patients with clinical node-positive breast cancer who have residual disease after neoadjuvant chemotherapy.
Retrospective observational study using the National Cancer Database from 2016 to 2021.
Analyzed patients with clinical T1-T4, N1-N3 breast cancer receiving neoadjuvant chemotherapy and classified the axillary procedures performed: SLNB alone, SLNB followed by ALND, or ALND alone.
Logistic regression was utilized to identify factors linked to the omission of ALND, adjusting for sociodemographic, geographic, and clinical variables.
Among 38,559 patients, 18.49% underwent SLNB alone, 36.95% SLNB followed by ALND, and 44.55% ALND alone.
Over the study period, the use of SLNB alone and SLNB + ALND increased, while ALND alone decreased.
Patients treated at comprehensive community and integrated network programs had higher odds of receiving SLNB alone compared to academic programs (OR 1.32, 95% CI 1.22–1.43; OR 1.17, 95% CI 1.07–1.27; OR 1.54, 95% CI 1.33–1.78).

Cite This Study

Rademacher et al. (2026) studied this question.

synapsesocial.com/papers/6a40bb1461bb0a67205c6c42 https://doi.org/10.1245/s10434-026-19968-5

View Full Paper

Ask AI

Bookmark

Implication

Retrospective observational study evaluates factors leading to omission of axillary dissection in patients with residual nodal disease after neoadjuvant chemotherapy, indicating evolving treatment...

Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Factors Associated with Omission of Axillary Lymph Node Dissection for Patients with Clinical Node-Positive Breast Cancer Who have Residual Nodal Disease on Pathology After Neoadjuvant Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider